Your lab queue is empty.
Shipping and taxes calculated at checkout.
For research purposes only
Documentation on compound structure, mechanisms, analytical verification, and the research peptide market. Every article cites peer-reviewed literature and is written for research use only.
A comparison of manual literature and catalog lookups against keyword search across compounds, glossary, articles and community posts, using GH secretagogue compounds as worked examples. For research purposes only.
How CJC no DAC, a modified GHRH(1-29) analog, is used as a ligand in GHRH receptor binding and competition studies, with notes on assay design, controls and comparison compounds. For research purposes only.
A federal order now describes Rats Army's published COAs as misleading. The replacement question is really a verification question — here is the checklist, and how Prove It Performance documents every batch. For research purposes only.
A federal court accepted Rats Army owner Tyler Jordan Hall's guilty plea in May 2025, and the FDA published a five-year import debarment order in January 2026. What the record documents — including the misleading COAs — and what it means for researchers.
A research overview of CJC No DAC, a GHRH(1-29) analog engineered for resistance to enzymatic degradation, and how it is studied in pituitary cell culture and other in vitro GH-axis research models. For research purposes only.
A research overview of ipamorelin, a synthetic pentapeptide studied as a selective growth hormone secretagogue receptor agonist. Covers molecular structure, ghrelin receptor pharmacology, selectivity profile compared to first-generation GHRPs, and why it is studied alongside CJC without DAC in GH axis research. For research purposes only.
A practical framework for qualifying research peptide suppliers based on documentation standards, analytical testing requirements, and quality infrastructure. Covers batch-specific COA verification, HPLC and mass spectrometry requirements, and endotoxin testing — for research purposes only.
A research overview of sermorelin acetate, a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone releasing hormone. Covers molecular structure, GHRH receptor pharmacology, how it differs mechanistically from ghrelin-based GH secretagogues, and its role in GH axis research. For research purposes only.
A research overview of tesamorelin, a synthetic stabilized analog of the full-length 44-amino-acid growth hormone releasing hormone. Covers molecular architecture, GHRH receptor pharmacology, the mechanism of GH-axis pulsatile signaling, and how tesamorelin's structural stabilization distinguishes it from native GHRH and shorter synthetic fragments in research models. For research purposes only.
What separates research-grade documentation from marketing claims? Technical breakdown of CLIA certification, GMP compliance, testing methodology comparison, and CoA evaluation criteria for performance research procurement.
Performance research comparison of GLP-1, GIP, and dual GIP/GLP-1 agonist peptides including tirzepatide — receptor binding mechanisms, metabolic signaling pathways, and published preclinical findings.
Performance research comparison of Epitalon, FOXO4-DRI, and GHK-Cu examining telomerase activation, senescent cell apoptosis mechanisms, and copper-peptide tissue remodeling in published literature.
Performance research comparison of BPC-157, TB-500, and Epitalon: amino acid sequences, molecular weights, proposed mechanisms, and cell culture model data from published literature.
Head-to-head comparison of GHS peptides for performance research labs. Molecular weights, receptor binding, structural modifications, and published pharmacological specifications.
Performance research comparison of Semax, Selank, and Dihexa examining BDNF modulation, GABA-A receptor interactions, HGF/c-Met signaling, and published preclinical findings. For research purposes only.
Thermal stability is a property of the sequence, not of peptides as a class. Which residues drive oxidation, which motifs drive deamidation and hydrolysis, and how to read a sequence for its liabilities before a stability problem appears. For research purposes only.
A lipidated analog carrying non-standard residues is a different analytical problem than a plain peptide. Where fatty acid side chains distort chromatography, what mass spectrometry has to confirm beyond the backbone, and which impurities a purity percentage will not surface. For research purposes only.
The chromatogram carries the evidence the purity percentage discards. How to read retention time, peak symmetry, baseline quality, and integration marks to judge whether a reported number is supported.
The BPC-157 record is preclinical: cell and biochemical work plus a substantial body of whole-animal injury models, and no controlled human efficacy data. Where each rung of evidence stops, and how to tell a mechanistic finding from a claim built on top of one. For research purposes only.
Purity is a chromatographic share of detected material. Potency is measured biological activity. Why the two diverge, what causes the gap, and how activity is established when a purity figure cannot.